Odefsey rilpivirine/emtricitabine/tenofovir alafenamide regulatory update

The European Commission approved Gilead’s Odefsey rilpivirine/emtricitabine/tenofovir alafenamide to treat HIV-1 infection in patients ages >=12 with HIV-1 RNA levels <=100,000 copies/mL and without k...